Lv1
80 积分 2025-02-10 加入
The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial
7个月前
已完结
Tarlatamab in Small-Cell Lung Cancer
7个月前
已关闭
Tarlatamab in Small-Cell Lung Cancer
7个月前
已关闭
Maintenance tarlatamab extends overall survival
7个月前
已完结
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas
7个月前
已完结
Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series
8个月前
已完结
Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer
8个月前
已关闭
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report
8个月前
已完结
Class I HLA Alleles are associated with an increased risk of osimertinib-induced hypersensitivity
8个月前
已完结
Osimertinib-Induced Toxic Epidermal Necrolysis – A Case Report
8个月前
已关闭
皖公网安备34019202002308
